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ABSTRACT
It has been estimated that currently over 150 million men worldwide suffer from erectile dysfunction (ED) and by 2025, the figure will increase 
beyond 322 millions. ED is the inability to achieve, and/or maintain penile erection sufficient for satisfactory sexual intercourse, and was previously 
regarded as the part of aging. It is associated with certain diseases and life style habits with a cause-effect relationship, including diabetes mellitus, 
hypertension, dyslipidemia, and cigarette smoking. Internationally, most of the men with ED fail to pursue treatment due to the complex nature of 
sexuality, taboos, cultural restrictions, and acceptance of ED as a normal sequel of aging. In this review, we discussed the physiology, diagnosis, and 
risk factors associated with ED and current treatment strategies for ED.
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INTRODUCTION
Penile erection is an integrated part of male sexual behavior and is 
dependent on coordinated activities in the central and peripheral 
nervous systems, as well as on intact inter- and intra-cellular signaling 
pathways in the penis. Erectile dysfunction (ED) is next only to 
premature ejaculation in prevalence among male sexual problems [1]. 
However, it is known that medical practitioners often do not inquire 
about it in patients in whom it may not be the complaint [2]; even 
though, risk factors for it may be present; especially hypertension, use 
of antihypertensive drugs, diabetes mellitus, and smoking [3]. This 
situation is surprising because ED has a major negative impact on 
quality of life [4] and for this reason, it has been suggested that even 
if patients do not mention ED problems, physicians should not neglect 
to inquire about them [5]. It has been estimated that currently over 
150 million men worldwide suffer from ED and by 2025, the figure 
will increase beyond 322 millions [6]. The prevalence of ED increases 
significantly with age, from approximately 10% between age 40 and 
49 years to over 50% after age >70 years [7].
PHYSIOLOGY
Penile erection is a complex neurovascular event involving the interaction 
between different systems: The nervous system (central and peripheral) 
and the penile (arterial and trabecular) smooth muscle system. The 
tone of penile smooth muscle is a key determinant of the hemodynamic 
events that maintain penile flaccidity or allow erection. The cavernosal 
arteries supply blood to the corpora cavernosa of the penis (through 
the pudendal artery), whereas the emissary veins running through the 
tunica albuginea allow blood to flow out of the penis. In the flaccid penis, 
smooth muscle cells of corpora cavernosa are contracted and penile 
blood inflow is low. During erection, relaxation of trabecular smooth 
muscle results in an increased blood flow and pressure in the corpora 
cavernosa and an expansion of sinusoidal spaces (Fig. 1).  The expanded 
corpora cavernosa cause mechanical compression of the emissary 
veins, restricting the venous outflow from the cavernosal spaces and 
facilitating an entrapment of blood in the cavernosal sinusoids. This 
blood engorgement finally results in penile rigidity [8].
Several neurotransmitters and endothelial factors have been shown 
to control erectile function by modulating the penile vasculature and 
smooth muscle tone of corpora cavernosa [9]. The correct balance 
between relaxant and contractile factors is required to determine 
the functional state of the penis, finally resulting in a normal erectile 
function.
DIAGNOSIS AND RISK FACTORS
Diagnosis is best done by means of a detailed sexual history. The second 
is to ascertain the severity of the problem. This can be done objectively 
with questionnaires, for example, international index of erectile 
function (IIEF) [10] or it can be ascertained from the history. The third 
is to identify treatable conditions that may be relevant to the cause 
of the ED. Such conditions might include diabetes, hyperlipidemia, 
depression, hypertension, or hypogonadism (Table 1). Some of these 
conditions will be identified during history and examination, whereas 
others will require special investigations. The fourth objective is to 
identify patients who have causes of ED which might be amenable to 
specific treatment (Table 2) and also by physical examination (Table 3). 
The following sections will give a survey of the clinical studies that have 
addressed the possible role played by diabetes, cardiovascular diseases 
(CVD), obesity, and smoking in the development of ED.
DIABETES
Diabetes is associated with accelerated large vessel atherosclerosis and 
microvascular arterial disease, autonomic neuropathy, dyslipidemia, 
concomitant hypertension, and endothelial dysfunction. Diabetic men 
are 3 times as likely to develop ED as non-diabetic men. The cause is 
multifactorial, but most commonly reflects endothelial dysfunction and 
autonomic neuropathy. In a recent prevalence and risk factors analysis 
for ED using the IIEF-5, in men aged 20-80 years undergoing a health 
investigation, it was shown that 32.2% of men had ED according to the 
IIEF-5 and that the most important risk factor was diabetes [11]. ED in 
diabetes may be secondary to a neuropathic condition of the autonomic 
penile nerves. Indeed, it has been shown that there is a functional 
penile neuropathic condition of the cholinergic nerves in the corpus 
cavernosum of diabetic impotent patients that may be responsible for 
the ED.
This relationship between autonomic neuropathy and impotence in 
diabetes was studied in human tissue obtained during implantation 
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of a penile prosthesis in 19 impotent diabetic and 15 non-diabetic 
patients. The functional status of penile cholinergic nerves was 
assessed by evaluating acetylcholine accumulation, synthesis, and 
release using tritiated choline. Tritiated choline accumulation and 
tritiated acetylcholine synthesis and release were significantly reduced 
in the corporeal tissue from diabetic patients compared to that from 
non-diabetic patients, and no differences were found between insulin-
dependent and non-insulin-dependent diabetic patients [12].
CVD
There are several pieces of evidence in preclinical pharmacology and in 
clinical pharmacology that CVD represent a risk factor for ED. It is now 
generally accepted that the prevalence of CVD, such as ED, increases 
with age, but CVD by themselves are one of the major risk factor for ED. 
Overall, atherosclerotic vascular disease can account for almost 50% of 
the ED in men over 50 years of age. Heart disease and its associated risk 
factors, such as hypertension and low serum high density lipoprotein 
cholesterol, are significantly correlated with ED as demonstrated in 
the Massachusetts Male Aging study [13]. However, at present, there 
is an increasing interest in the possibility that ED represents an early 
sign of the existence of CVD, and that diagnosis of ED in an otherwise 
healthy patient could be considered an indication of a more systemic 
endothelial and vascular dysfunction.
Obesity
Healthy lifestyle factors are associated with maintenance of erectile 
function in men and there are several studies that have correlated 
life-style with ED. In an early study conducted in 1999 by Chung [14], 
ED was evaluated in 325 patients that were classified into 2 groups 
according to body weight: <120% and 120% of the ideal body weight. 
In this study, several erectile capacities were compared and a penile 
duplex ultrasonography analysis performed. In patients with obesity, 
there was a statistically significant decrease in the quality of residual 
erectile function measured as penile rigidity. Interestingly, 43% of 
the obese patients also displayed a significantly increased prevalence 
of vascular risk factors versus 30% in the non-obese, and 62% of 
the obese patients displayed a significant vascular impairment as 
assessed by duplex ultrasound versus 42% in the non-obese patients. 
However, when only the patients without any vascular risk factors 
were analyzed, no significant difference between the 2 groups was 
noted in the quality of residual erectile function and in the prevalence 
of penile vascular impairments (p>0.05), suggesting that obesity in 
itself does not seem to be an underlying factor, but does impose a 
risk to vasculogenic impotence by promoting development of chronic 
vascular disease.
Smoking
It is important to point out that virtually every part of the body, 
including the urological system, is adversely affected by smoking. 
Smoking is a powerful predictor of ED; however, cessation may restore 
normal function. Cigarette smoke also exerts adverse effects on 
sperm motility and count [15]. At the molecular level, several changes 
associated with smoking have been documented in man. In particular, it 
has been shown that smoking causes an impaired penile flow. Cigarette 
smoking also interferes with the potency of intracavernous papaverine 
and prostaglandin E1 (PGE1), clearly indicating that smoking reduces 




The introduction of phosphodiesterase type 5 inhibitors (PDE5Is) 
in 1998, has clearly revolutionized the management of ED. Oral 
pharmacotherapy PDE5 is an enzyme that hydrolyzes cyclic guanosine 
monophosphate in the cavernosum tissue of the penis. Inhibition of 
PDE5 results in increased arterial blood flow leading to smooth muscle 
relaxation, vasodilatation, and penile erection. Three potent selective 
PDE5 inhibitors are currently licensed with proven efficacy and safety 
for the treatment of ED.
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Sildenafil
Sildenafil was the first PDE5 inhibitor and >20 million men have been 
treated in the 6 years since its launch. It is effective (erection with 
rigidity sufficient for vaginal penetration) after 30-60 minutes from 
administration [17]. Its efficacy is reduced after a heavy fatty meal 
(reduced, i.e., prolonged absorption). It is administered in doses of 25, 
50, and 100 mg. The recommended starting dose is 50 mg and adapted 
according to the response and side effects. Efficacy may be maintained 
for up to 12 hrs [18].
Tadalafil
Tadalafil is effective from 30 minutes after administration, but its peak 
efficacy is expected in about 2 hrs [19]. Efficacy is maintained for up to 
36 hrs [20]. Its efficacy is not influenced by food. It is administered in 
10 and 20 mg doses. The recommended starting dose is 10 mg and is 
adapted according to the response and side effects.
Vardenafil
Vardenafil is effective after 30 minutes from administration. Its effect 
is reduced by a heavy fatty meal (>57% in fat). It is administered in 
5, 10, and 20 mg doses [21]. The recommended starting dose is 10 mg 
and is adapted according to the response and side effects. In vitro, it is 
10-fold more potent than sildenafil; however, this does not necessarily 
imply greater clinical efficacy [22]. Adverse events are generally mild in 
nature and self-limited by continuous use.
Contraindications
Concomitant (e.g., within 24 hrs for sildenafil and vardenafil, and 48 hrs 
for tadalafil) use of nitrate-containing medications (e.g., nitroglycerin, 
isosorbide dinitrate) is an absolute contraindication to PDE5Is use, as 
it can cause severe hypotension that can result in death. PDE5Is for 
patients who have recent serious cardiac events, poorly controlled 
hypertension, unstable angina or retinitis pigmentosa should be used 
with caution [23]. Coexisting cardiac conditions including stable 
coronary artery disease and heart failure do not post higher risk 
of cardiac ischemia, coronary vasoconstriction or worsening of the 
hemodynamic profile on exertion [24,25].
Adverse events
Adverse events for all three PDE5Is are generally mild and well-tolerated. 
Common side effects are similar for all three PDE5Is (Table 4). These 
include headache, flushing, dyspepsia, and nasal congestion. Other 
side effects specific to individual drug include musculoskeletal pain 
(3-6% with tadalafil), changes in color perception and light sensitivity 
(sildenafil and vardenafil) [26]. These visual changes are due to 
crossover effects of the drugs on PDE6, an isoform of PDE in the retina. 
A significantly more severe visual adverse event recently associated with 
PDE5Is is non-arteritic ischemic optic neuropathy, known to be the most 
common acute optic neuropathy and ranks second only to glaucoma as 
a cause of acquired optic neuropathy that can lead to sudden blindness.
Data are from the European Medicine Evaluation Association statements 
on product characteristics.
Apomorphine
Apomorphine is a centrally acting drug (dopamine agonist, mainly D2) 
that improves erectile function by enhancing the natural central erectile 
signals that normally occur during sexual stimulation. It is administered 
sublingually on demand in 2 or 3 mg doses. Apomorphine has been 
approved for ED treatment in many countries but not in the United 
States. Efficacy rates (erections hard enough for intercourse) range 
from 28.5% to 55% [27]. Due to rapid absorption, 71% of erections 
are achieved within 20 minutes. The most common adverse events are 
nausea (7%), headache (6.8%), and dizziness (4.4%).
Topical pharmacotherapy
Several vasoactive drugs (2% nitroglycerin, 15-20% papaverine gel, 
and 2% minoxidil solution or gel) have been used for topical application 
to the penis [28]. Adverse events include skin and glans erythema, 
burning sensation, allergic reactions, and side effects to the partner 
(hypotension, headache) due to absorption from the vagina.
Vacuum constriction device
This ED therapy functions via mechanical rather than pharmacological 
mean. It includes a plastic cylinder connecting to a vacuum-generating 
source powered manually or by battery. When placed on the penis, 
negative pressure provokes engorgement of blood to the sinusoidal 
tissue of the penile shaft and glands. An elastic ring is applied to the 
base of the penis to prevent egress of the trapped blood to enhance 
the rigidity for sexual activity. Despite several advantages such as no 
systemic side effects, high efficacy, low cost per treatment (after the 
initial expense for the device), the satisfaction rate of this device was 
only about 60-80% with a significant drop-out rate [29-31].
Second-line therapy
Intracavernosal injection
Available since the 1980s, intracavernous injection with single or 
combination vasoactive agents (commonly alprostadil, papaverine, 
phentolamine, and moxisylyte) was once the most frequently used 
therapies for ED before the PDE5Is’ era. Currently, for ED cases 
refractory PDE5Is (e.g. post-radical prostatectomy, severe diabetes or 
CVD) or when PDE5Is are contraindicated, intracavernous injection 
remains an effective ED treatment, either alone or in conjunction with 
other ED therapies such as PDE5Is. Proper selection of candidates 
(e.g., adequate dexterity for needle manipulation, absence of bleeding 
diathesis, etc.) and proper education is the key to successful treatment 
with intracavernous injection.
Transurethral medication
Alprostadil used in intracavernous injection can be applied 
transurethrally at a higher dose (250-1000 µg) as a therapy for ED 
with a success rate of 40-69% [32-35]. Adverse events associated with 
transurethral alprostadil include urethral pain and injury, vasovagal 
reflex, hypotension, and priapism (<0.1%). Although it devoid the need 
of needle injection, its effectiveness is significantly lower than when 
administered intracavernously. The use of penile constriction ring at 
the base has been advocated to enhance the efficacy of transurethral 
Table 3: Critical aspects of the physical examination
Genitalia Size and shape of penis
Abnormalities of the prepuce including 
phimosis
Palpable plaque signifying Peyronie’s disease







Vascular system Blood pressure assessment
Table 4: Common adverse events of the three PDE5 inhibitors
Adverse event Sildenafil (%) Tadalafil (%) Vardenafil (%)
Headache 12.80 14.50 16
Flushing 10.40 4.10 12








Back pain – 6.50 –
Myalgia – 5.70 –
PDE5: Phosphodiesterase type 5
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alprostadil and to reduce the risks of hemodynamic adverse events by 
slowing the rate of systemic absorption of the drug [36].
Testosterone replacement therapy
Androgens regulate erectile physiology via multiple mechanisms [37]. 
The decline in serum bio-available testosterone with aging can 
contribute to the severity of ED. When properly diagnosed and 
treated, testosterone replacement has been shown to be safe and 
effective in enhancing sexual desire and the efficacy of other forms of 
ED therapies [38,39]. Testosterone replacement can be administered 
transdermally, orally, intramuscularly or via buccal mucosa.
Penile prosthesis
The insertion of a penile prosthesis, which can be either a 
semirigid/malleable type made of silicone rubber with a central 
intertwined metallic core or hydraulic prosthesis that can be inflated 
or deflated through activation of scrotal pump controlling water flow 
from a suprapubic reservoir to the cylinders placed inside the corporal 
bodies of the penis, can virtually guarantee an erection for successful 
intercourse [40]. The surgical technique of penile prosthesis placement 
has been significantly modified and most experts can perform it with a 
single longitudinal incision through the ventral part of the penis as an 
outpatient procedure [41]. Large studies demonstrated a satisfaction 
rate >95% [42].
There is little interference in the orgasm, ejaculatory or urinary function, 
particularly with the hydraulic prosthesis. Mechanical failure of the 
prosthesis can occur, particularly with the hydraulic prosthesis, at a 
rate of 5-20% in the first 5 years [23]. Infection rate of penile prosthesis 
has been reduced in the recent years as a result of improved surgical 
techniques, use of prophylactic antibiotics and modification of the 
prosthesis materials that allow for antibiotic impregnation and elution. 
It should be noted that placement of penile prosthesis is irreversible 
as the corporal tissue is permanently altered, making it not possible to 
achieve physiologic erection. Thus, candidates for this surgical therapy 
for ED should be carefully selected and counseled.
Sex therapy
Before 1970s, individual psychotherapy was the typical treatment for 
sexual dysfunction. Evidently, ED can be a cause and a consequence 
of psychosocial stress. Many of the approaches developed in the 
1980s and 1990s are still currently in use. These include behavioral 
therapy, dual-sex therapy of Masters and Johnson, corporal approach, 
hypnotherapy, and group therapy. With the introduction of effective 
Pharmaco therapies, particularly the PDE5Is, the use of sex therapy 
for ED has clearly declined worldwide. Sex therapy, however, still plays 
an important role for other forms of sexual dysfunction including 
premature ejaculation, desire, arousal and orgasm problems, and other 
less common disorders.
Some natural products in treatment of erectile-dysfunction 
activity
Despite the world-wide interest in Viagra and the influence it has had 
on the search for a natural product which can deal effectively with the 
problem of ED, no such breakthrough has become a reality. Herbal 
medicines are widely available and are often used because of the belief 
that they are a safe alternative to conventional medication.
Dehydroepiandrosterone (DHEA)
DHEA is the major secretory steroidal hormone of the adrenal gland 
and its isolation dates back to 1934. In a comprehensive study [43] of 
17 hormones it was shown that only DHEA showed a strong inverse 
Fig. 1: Schematic representation of neurofunctional anatomy of penile erection
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correlation to E-D. A more recent investigation [44], was carried out on 
40 men of mean average age 56 to study the effects of DHEA on patients 
with ED. The results suggest that daily oral supplementation of the 
hormone produces a rise in serum levels of DHEA, concomitant with 
increase in sexual performance and satisfaction.
Yohimbine
Yohimbine is an indole alkaloid with α2-adrenergic blocking activity. 
It comes from the bark of Corynanthe yohimbe and its first isolation 
was in the early 1930s. The bark of the tree is traditionally used to 
enhance sexual prowess and virility. Renewed interest in yohimbine 
for E-D has prompted several new investigative (including chemical) 
trials. Indications are that in some cases yohimbine can improve sexual 
performance [45]. There are, however, indications of undesirable side-
effects such as hypertension, anxiety, manic symptoms, and undesirable 
interactions with commonly used medications [46].
l-Citrulline
When l-citrulline [(N5-aminocarbonyl)-l-ornithine] is part of a 
formulation with calcium phosphate and other extenders, it is marketed 
under the trade name STIMULIN. The preparation is claimed to improve 
sexual stamina and ease E-D. The active ingredient in the formulation is 
l-citrulline which occurs naturally in watermelons. L-citrulline was first 
isolated in the 1930s, but its use as dietary supplement is of relatively 
recent origin. The activity of l-citrulline is attributed to its ability to 
release NO which, in turn, results in increased blood flow to the body, 
including the penis.
Berberine
Berberine is an alkaloid widely distributed in nature and occurs in 
Berberis plants such as Berberis aristata and Berberis vulgaris have 
undertaken a very detailed study on the relaxation of the corpus 
cavernosum and raised intravenous pressure by berberine in rabbit. 
For these tests, male New Zealand rabbits were used to obtain the 
corpus cavernosum tissue and the intravenous pressure change 
measured after intercavernosal injection of berberine. The overall 
results show that berberine possesses a relaxant effect on the rabbit 
corpus cavernosum tissue which is attributable to both endothelial-
dependent and -independent properties.
Papaverine and prostaglandin E1
A combination of two natural products from Papaver somniferum and 
from sheep seminal vesicle tissue, respectively, has received renewed 
attention as a potential combination against male impotence [47]. It 
should be emphasized that both papaverine and prostaglandin E1 are 
recognized vasodilators. Research findings based on a clinical trial on 
100 impotent male patients indicated that papaverine plus PGE1 was 
more effective than PGE1 alone. The procedure was not without its 
complications, however, and reinforced the earlier findings [48] that 
papaverine, phentolamine, and PGE1, as a combination gave rise to side 
effects such as priapism [49] (extended erection), local fibrosis, and pain.
Forskolin
The source in nature of the diterpene forskolin is the Indian herb 
Coleus forskohlii. It is of relatively recent origin (1977) and possesses 
vasodilatory and cardiostimulatory properties. In view of the 
cyclic adenosine monophosphate dependent effects produced by 
forskolin, it has found use as an agent for the treatment of congestive 
cardiomyopathy, glaucoma, and asthma. Forskolin has also been 
investigated as an intracavernosal vasoactive agent in the management 
of vasculogenic impotence. In in-vitro tests, forskolin and PGE1 alone 
caused concentration dependent relaxation. Combination of the two 
agents resulted in synergistic response [50]. Clinical investigation in 
31 patients showed no adverse effects. Overall 61% of these reported 
improvement in rigidity of the penis and/or erection duration using a 
combination of forskolin, papaverine, phentolamine, and PGE1.
Tribulus terrestris
T. terrestris (devil’s thorn) is used medicinally as a tonic for diarrhea and 
diseases of the throat and eyes. The work of Adimoelja [51] in Indonesia 
and Adaikan [52] in Singapore has drawn attention to a potential 
additional use of the extracts from T. terrestris. These researchers 
have presented evidence that protodioscin, a compound present in the 
T. terrestris extracts, can improve sexual desire and enhance erection. 
A commercial preparation of the T. terrestris preparation is sold under 
the trade name of Libilov.
Ginseng from Panex ginseng
The herbal tonic known commonly as ginseng enjoys extremely 
widespread use. Some chemical evidence supports the stimulatory 
action of the extract from P. ginseng or Panex quinquefolius, but the 
US Food and Drug Administration (FDA) have found no evidence of 
enhanced sexual experience resulting from its ingestion [51]. Earlier 
studies on Korean red ginseng [52] are in-line with the conclusions 
of the FDA and the authors state that ‘‘no complete remission of E-D 
was noted, but partial responses were reported.’’ Root extracts of 
ginseng contain a variety of compounds such as steroids, peptides, 
triterpenoidal d-glucosides, and specifically panax sapogenin.
Lipidic extract from Lepidium meyenii (maca)
The plant L. meyenii belongs to the Solanaceae and has been known and 
used in the Andean mountains for 2000 years. While it has nutritional 
value it is also employed by the Andean Indians for enhancing fertility 
and sexual behavior in both sexes [53].
Eurycoma longifolia extracts
E. longifolia (Simaroubaceae), commonly called Tongkat Ali, is native to 
the jungle of Malaysia [54]. Antimalarial, cytotoxic, anti-ulcer, and anti-
pyretic properties have been claimed for it over the years. Recently, it 
has figured prominently in the popular press on account of its reputed 
use to increase male virility. For this reason, several research groups 
have examined it for this property, notably using sexually experienced 
male rats [54]. It was found that rats treated with a specific dose of the 
extract, twice a day, displayed behavior of rats with enhanced sexual 
arousal [54].
Herbal medicine catuama
The combination of herbs, collectively known as ‘‘Catuama’’ in Brazil, 
consists of four plants cupana, Trichilia catigua, Zingiber officinalis and 
Ptychopetalum olacoides [55,56]. The individual components have also 
been used, separately, for centuries, for a variety of purposes (analgesic, 
antibacterial, cardiotonic, purgative, and vasodilatory). However, 
it is the combination of the four that, in more recent times, has been 
promoted as an aphrodisiac.
CONCLUSION
Raising the penis from a dependent position to an erect position is a 
complex neurovascular event modulated by psychological factors and 
hormonal status. ED is an important public health problem affecting 
over half of all men ages 40-70. Sildenafil offers the first orally effective 
symptomatic treatment of ED. Oral sildenafil therapy, while effective in 
circumventing the cause of ED, provides only short-term symptomatic 
relief of the condition. Whole patient management of ED might 
also include psychological or relationship counseling, treatment of 
associated underlying chronic conditions, and the use of natural agents 
shown to improve derangements in penile endothelial L-arginine-NO 
activity. Truly, successful treatment strategies for ED must include the 
interplay between the mind and the nervous, vascular, and endocrine 
systems that results in erection.
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